Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 3/20 | 0.32 |
| ▸ | NRAS | P01111 | 2/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.31 |
| ▸ | ATR | Q13535 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL23209481 | 0.99 | FLT3 (0.32) | FLT3NRASMAPK14ATR | |
| SCHEMBL31586595 | 0.87 | FLT3 (0.32) | FLT3NRAS | |
| SCHEMBL31160713 | 0.83 | JAK2 (0.35) | — | |
| SCHEMBL31423950 | 0.82 | ATR (0.32) | ATR | |
| SCHEMBL31423911 | 0.82 | ATR (0.32) | ATR | |
| SCHEMBL23233917 | 0.82 | CDK6 (0.39) | — | |
| SCHEMBL23209500 | 0.82 | CDK6 (0.39) | — | |
| SCHEMBL27232871 | 0.82 | CDK6 (0.39) | — | |
| SCHEMBL23209310 | 0.81 | JAK1 (0.36) | ATR | |
| SCHEMBL23209188 | 0.81 | JAK1 (0.35) | ATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4736856-A2 | BICYCLIC AMINES AS CDK2 INHIBITORS | Incyte Corporation (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4041731-B1 | BICYCLIC AMINES AS CDK2 INHIBITORS | INCYTE CORP (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20260022119-A1 | BICYCLIC AMINES AS CDK2 INHIBITORS | INCYTE CORPORATION | 2026-01-22 | — | — | US | disclosed |
| US-12466828-B2 | Bicyclic amines as CDK2 inhibitors | INCYTE CORPORATION (US) | 2025-11-11 | — | — | US | disclosed |
| US-20240174664-A1 | BICYCLIC AMINES AS CDK2 INHIBITORS | INCYTE CORPORATION | 2024-05-30 | — | — | US | disclosed |
| US-11851426-B2 | Bicyclic amines as CDK2 inhibitors | INCYTE CORPORATION (US) | 2023-12-26 | — | — | US | disclosed |
| US-20210107901-A1 | BICYCLIC AMINES AS CDK2 INHIBITORS | INCYTE CORPORATION | 2021-04-15 | — | — | US | disclosed |
| WO-2021072232-A1 | BICYCLIC AMINES AS CDK2 INHIBITORS | INCYTE CORPORATION (US) | 2021-04-15 | — | — | WO | disclosed |
| US-20210107901-A1 | BICYCLIC AMINES AS CDK2 INHIBITORS | INCYTE CORPORATION | 2021-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260022119-A1 | BICYCLIC AMINES AS CDK2 INHIBITORS | CCNA1, CDK1, CCNE1 | FLT3 2107/4885NRAS 518/4885MAPK14 1488/4885 |
| US-11851426-B2 | Bicyclic amines as CDK2 inhibitors | CDK2, CDK1, CCNI | FLT3 435/4885NRAS 337/4885MAPK14 644/4885 |
| US-20240174664-A1 | BICYCLIC AMINES AS CDK2 INHIBITORS | CDK2, CDK1, CCNI | FLT3 435/4885NRAS 337/4885MAPK14 644/4885 |
| US-20210107901-A1 | BICYCLIC AMINES AS CDK2 INHIBITORS | CDK2, CDK1, CCNI | FLT3 435/4885NRAS 337/4885MAPK14 644/4885 |
| US-12466828-B2 | Bicyclic amines as CDK2 inhibitors | CDK2, CDK1, CCNI | FLT3 435/4885NRAS 337/4885MAPK14 644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.